By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
An intravascular implant known as a vascular embolization device is used to stop bleeding from aneurysms, certain tumors (such as nephromas, hepatomas, and uterine fibroids), and arteriovenous malformations.
a process that stops the blood flow to a tumor or other aberrant region of tissue.
Blood flow to a particular vessel is stopped during embolization operations. AVMs, recurrent nosebleeds, severe traumas, and certain malignancies are among the ailments it addresses. Surgery is more intrusive than embolization, which is less traumatic to your body.
A tiny catheter is inserted into the blood arteries supplying the bleeding location to accomplish embolization. A range of various materials can then be utilized to block the bleeding arteries after carefully directing the catheter under imaging guidance to the safest and furthest place.
A technique termed uterine fibroid embolization is used to treat uterine fibroids, which are benign tumors of the uterus. You could heal more quickly as it doesn’t require significant surgery. Additionally, you might not require a hospital stay.
After uterine fibroid embolization, you can have discomfort or cramping for a few days. However, discomfort occasionally lasts for a few weeks. For a few days, you can also have minor nausea. For several weeks to months, some patients have vaginal bleeding or a greyish or brownish discharge.
Recovery following embolization normally takes a week to ten days. Pelvic pressure and discomfort following the surgery might be severe in the initial days. Similar to how you would feel when you have the flu or a cold, you can have chills, fever, and reduced energy.
The Global Vascular embolization device market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The vascular embolization tool DC Bead (specially regulated medical gadget) will be made available in Japan by Eisai Co., Ltd.
Hydrophilic microspheres formed of cross-linked polyvinyl alcohol polymer are found in DC Bead. It was created as an intravascular embolization device by Bio compatibles UK Limited (Bio compatibles), a business in the BTG International group, and is administered by catheter into specific blood arteries to produce selective embolization.
In more than 50 nations and territories throughout the world, including in Europe and the US, DC Bead is already marketed as an efficient embolization tool for the treatment of hepatocellular carcinoma (HCC) and other hyper vascularized tumors.
Hydrophilic microspheres (beads) formed of cross-linked polyvinyl alcohol polymer are found in DC Bead. It is administered via catheter into predetermined blood arteries as a vascular embolization device to accomplish selective embolization.
DC Bead’s ability to sustain embolization of selected blood arteries based on tumor size and vascular diameter is made possible by the beads’ tiny size and consistent spherical shape. Each embolization operation is verified by endoscopic examination of the targeted vessels.
Following its introduction in Japan, the device will be offered domestically in three bead sizes (100-300 micro-m, 300-500 micro-m, and 500-700 micro-m), allowing the user to choose the right bead size based on the vascular diameter, tumor size, and degree of intended embolization in the targeted blood vessel.
